Drug Database
Back to search

Poland· PL-100056724

Pulmozyme

A dornase alfa (desoxyribonuclease) product containing dornasum alfa, registered in Poland by Roche Polska Sp. z o.o.. The same ATC class is registered in 11 of our 19 countries.

ATC R05CB13

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedPulmozymeATCR05CB13REGISTER NO.PL-100056724PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dornasum alfaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dornase alfa (desoxyribonuclease) is registered in 11 of 19 countries.

Countries holding a registration under ATC R05CB13 (dornase alfa (desoxyribonuclease)), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search dornase alfa (desoxyribonuclease) products by name

Dornase alfa (desoxyribonuclease) · ATC R05CB13

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Dornasum alfa
Manufacturer
Roche Polska Sp. z o.o.
Country
Poland (PL)
ATC code
R05CB13
ATC class
Dornase alfa (desoxyribonuclease)
Defined daily dose
2.5 mg, Inhal
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

1 priced
  • gtin
    05909990375813
    30 amp. po 2,5 ml
    PLN 2411.63

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for dornase alfa (desoxyribonuclease).

Graded by severity as the source publishes them — 5 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dornase alfa (desoxyribonuclease) against other medicinesHow interaction checks work

Dornase alfa (desoxyribonuclease) · interactions on record

5 records

  • 5 moderate

Most severe, free to view

  • Insulin (human)A10AB01moderate
  • Insulin (human)A10AC01moderate
  • Insulin (human)A10AD01moderate
  • Insulin (human)A10AE01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dornase alfa (desoxyribonuclease) in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dornase alfa (desoxyribonuclease) products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Pulmozyme
  • Belgium · Pulmozyme
  • Bulgaria · Пулмозим
  • Cyprus · Pulmozyme
  • Czechia · Pulmozyme
  • Germany · Pulmozyme
  • Denmark · Pulmozyme
  • Estonia · Pulmozyme
  • Spain · Pulmozyme
  • Finland · Pulmozyme
  • France · Pulmozyme
  • United Kingdom (Northern Ireland) · Pulmozyme
  • Greece · Pulmozyme
  • Croatia · Pulmozyme Otopina Za Atomizator
  • Hungary · Pulmozyme
  • Ireland · Pulmozyme
  • Iceland · Pulmozyme
  • Italy · Pulmozyme
  • Lithuania · Pulmozyme
  • Luxembourg · Pulmozyme
  • Latvia · Pulmozyme
  • Netherlands · Pulmozyme Verneveloplossing
  • Norway · Pulmozyme
  • Portugal · Pulmozyme
  • Romania · Pulmozyme
  • Sweden · Pulmozyme
  • Slovenia · Pulmozyme
  • Slovakia · Pulmozyme

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/72f3a8c2-d92e-4138-a6c3-860d6188d6af
GET /v1/drugs/72f3a8c2-d92e-4138-a6c3-860d6188d6af?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do nebulizacji",
  "source": "urpl",
  "strength": "1 mg/ml",
  "packaging": "05909990375813 ¦ Rp ¦ 8480\n30 amp. 2,5 ml",
  "substance": "Dornasum alfa 2.5 mg",
  "common_name": "Dornasum alfa",
  "pl_product_id": "100056724",
  "pozwolenie_nr": "03758",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about dornase alfa (desoxyribonuclease).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console